Register Now: Does Your Pharmaceutical WMS Grow with You?
News|Articles|November 26, 2024

Pharma Pulse 11/26/24: Early Access for Innovative Therapies, Trump Names Picks for FDA and CDC & more

The latest news for pharma industry insiders.

Passage to Asia: Early Access for Innovative Therapies

Pharma looks to take advantage of expanded access programs across Asia-Pacific region.

Trump Names Picks for Top Jobs at FDA and CDC and Also Surgeon General

Marty Makary, M.D., M.P.H., as FDA administrator may be the least controversial of Trump's picks for the top healthcare jobs so far.

Novo Nordisk Foundation Targets US, Europe After Obesity Boost

The world’s largest philanthropic fund that ultimately controls Novo Nordisk A/S will ramp up its investments outside of Denmark after cashing in on the weight-loss drug boom.

VIVIO Extends Open Market Specialty Drug Platform to Solve Our PBM Crisis

VIVIO announced PrecisionCare One™, an extension of its proven open-market specialty drug management platform to include all drugs. This builds on VIVIO’s prior success in managing complex specialty medications across pharmacy and medical benefits, where its clinical-first approach has delivered cost-effective outcomes in oncology, rheumatology, multiple sclerosis, HIV, and other specialized therapeutic areas.

Kotter on LinkedIn

⛓️‍💥 Navigating disruptions and regulatory concerns is no easy feat for pharmaceutical leaders.

💡 In the first of a three part video series with, Kotter Managing Director and Head of R+D Gaurav Gupta details the types of regulatory pressures and disruptive factors influencing the pharmaceutical industry and how leaders can adapt and be prepared for what's to come.

👉 Catch Gaurav’s insights here: https://bit.ly/40ZePJe.

#Pharmaceuticals #Pharma #Supplychain

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs


Related to this article

CVS Pharmacy Sign at Storefront Entrance | © Mark Roger Bailey - stock.adobe.com 557616813
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.